In this issue of Insights, we summarize a recent discussion held with a number of pharmaceutical companies on US health policy, potential priorities for the Trump administration, and yes, pricing. Tim Wilsdon, an expert in international policy issues affecting the development and commercialization of medicines, led the discussion.
To read more, click the link below.
Identifying high-impact solutions to address racial and ethnic health disparities in lupus: A consensus-based approach
This study used a consensus-based approach to identify high-impact solutions for reducing racial and ethnic health disparities in lupus. Through a literature...